The ASCEND Study: A Study to Investigate the Safety and Clinical Effect of Nexagon to Treat Slow Healing Diabetic Foot Ulcers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00820703|
Recruitment Status : Terminated (For business reasons)
First Posted : January 12, 2009
Last Update Posted : August 31, 2010
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Foot Ulcer||Drug: Nexagon® Drug: Nexagon® vehicle||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Prospective, Double-blind, Vehicle-controlled, Dose-escalation, Single-center Study of the Safety and Clinical Effect of Nexagon® in the Treatment of Participants With Diabetic Foot Ulcers|
|Study Start Date :||April 2009|
|Actual Primary Completion Date :||November 2009|
|Actual Study Completion Date :||December 2009|
- To evaluate the safety and clinical effect of Nexagon® administered topically to diabetic foot ulcers.
- To select the optimal dose(s) which can be used in future trials of Nexagon® in diabetic foot ulcers
- To pilot the collection of data that may be considered useful in planning future studies of Nexagon® administered topically to diabetic foot ulcers.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00820703
|Auckland, New Zealand|